Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

SRR5088854

a83a5a19-55ed-578f-8461-4820c4295c05

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.400
  • INTERFERON_GAMMA_RESPONSE+0.200
  • MYC_TARGETS_V2+0.200
  • OXIDATIVE_PHOSPHORYLATION+0.200
  • DNA_REPAIR+0.100
  • MYC_TARGETS_V1+0.100
  • ADIPOGENESIS+0.000
  • ALLOGRAFT_REJECTION+0.000
  • KRAS_SIGNALING_DN+0.000
  • PANCREAS_BETA_CELLS+0.000

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
  • ANGIOGENESIS-0.400
  • APICAL_JUNCTION-0.400
  • E2F_TARGETS-0.400
  • G2M_CHECKPOINT-0.400
  • NOTCH_SIGNALING-0.400
  • TGF_BETA_SIGNALING-0.400
  • TNFA_SIGNALING_VIA_NFKB-0.400
  • APICAL_SURFACE-0.300
  • COAGULATION-0.300

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-ZF-A9R5-01A-12R-A42T-07
bladder-landscape@3
0.900
20a4a9b5b-90d9-4789-af04-f931433808c1
colon-landscapes@1
0.835
36ca5eb09-d104-4305-b3ec-4d6e8a0c2850
melanoma-umap@29
0.827
4TCGA-XF-AAN1-01A-31R-A42T-07
bladder-landscape@3
0.810
520040020.LumA
breast-umap@18
B0.807
6TCGA-62-A472-01A-11R-A24H-07
lung-landscapes@6
cohortA10.800
7b6a7e87e-2674-4a48-a3c2-c8a9806762b5
melanoma-umap@29
0.794
8SAMN03290916
melanoma-umap@29
0.790
9SRR10900001
melanoma-umap@29
0.789
10s0095165
melanoma-umap@29
0.786

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 6 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.400Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.200Idelalisib— uncovered
MYC_TARGETS_V20.200Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.200Remibrutinib— uncovered
DNA_REPAIR0.100Idelalisib— uncovered
MYC_TARGETS_V10.100Inavolisib— uncovered